GLMD
Galmed Pharmaceuticals Ltd.NASDAQHealthcare$0.54-3.52%ClosedMarket Cap: $3.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.15
P/S
0.00
EV/EBITDA
0.06
DCF Value
$3.88
FCF Yield
-222.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.8%
ROA
-40.3%
ROIC
-36.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | NaN% | $-2.1M | $-1.9M | $-0.35 | — |
| Q2 2025 | $0.00 | NaN% | $-2.1M | $-2.5M | $-0.63 | — |
| Q1 2025 | $0.00 | NaN% | $-1.3M | $-1.1M | $-0.62 | — |
| Q4 2024 | $0.00 | NaN% | $-1.6M | $-3.2M | $-46.42 | — |
| FY 2024 | $0.00 | -Infinity% | $-6.3M | $-7.5M | $-8.08 | — |
| Q3 2024 | $0.00 | NaN% | $-2.0M | $-1.9M | $-27.69 | — |
| Q2 2024 | $0.00 | -Infinity% | $-1.2M | $-1.1M | $-2.13 | — |
| Q1 2024 | $0.00 | -Infinity% | $-1.4M | $-1.3M | $-0.23 | — |
| Q4 2023 | $0.00 | -Infinity% | $-2.2M | $-2.0M | $-0.40 | — |
| FY 2023 | $0.00 | -Infinity% | $7.5M | $-6.9M | $-29.95 | — |
| Q3 2023 | $0.00 | -Infinity% | $-1.5M | $-1.5M | $-0.24 | — |
| Q2 2023 | $0.00 | -Infinity% | $-1.9M | $-1.6M | $-0.95 | — |